Patients with a rare neuromuscular disease called Lambert-Eaton myasthenic syndrome are now terrified the cost for their treatment could soar to $100,000 without insurance because of a quirk in pharmaceutical approvals and pricing; Bloomberg Philanthropies will donate $50 million to 10 states fighting the opioid epidemic; Republican lawmakers in the GOP Doctors Caucus expressed their concerns about President Trump's controversial proposal to lower drug prices in a meeting this week with HHS Secretary Alex Azar.
Patients with a rare neuromuscular disease called Lambert-Eaton myasthenic syndrome have long survived on an inexpensive, sometimes free chemical called 3,4-DAP thanks to the generosity of a tiny, family-run drug maker. But they are now terrified the cost for their treatment could soar to $100,000 without insurance because of a quirk in pharmaceutical approvals and pricing, STAT News reported. The old compound was never formally approved by the FDA, but the agency recently cleared a nearly identical formulation from Catalyst Pharmaceuticals, which now has the ability to charge what could be hundreds of thousands of dollars for a medicine it did not invent and that costs almost nothing to make. Catalyst could also block older forms of the drugs from being given to patients.
Bloomberg Philanthropies will donate $50 million to 10 states fighting the opioid epidemic. Former New York mayor Michael Bloomberg is scheduled to announce the 3-year program Friday morning during the second day of a health conference in Washington hosted by another of his ventures, the Bloomberg American Health Initiative, The Washington Post reported. The effort will support current programs and encourage new approaches. The CDC, the Pew Charitable Trusts, Johns Hopkins, and a publid health nonprofit called Vital Strategies will also take part in the Bloomberg program.
Republican lawmakers in the GOP Doctors Caucus expressed their concerns about President Trump's controversial proposal to lower drug prices in a meeting this week with HHS Secretary Alex Azar, The Hill reported. At issue is the proposal to lower certain Medicare drug prices by tying them to lower prices paid in other countries. The administration has argued that Medicare Part B currently essentially pays drug companies whatever price they want for their products, and that the system needs to change. In another sign of GOP concerns, 55 conservative groups wrote a letter on Wednesday calling for the proposal to be withdrawn, warning of “price controls.”
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More